AVITA Medical (RCEL) Liabilities and Shareholders Equity (2020 - 2026)

AVITA Medical (RCEL) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $56.4 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 29.25% year-over-year to $56.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $247.8 million (down 28.37% YoY) and the FY2025 annual result came in at $56.4 million, down 29.25% from the prior year.
• Liabilities and Shareholders Equity retreated to $56.4 million in Q4 2025, from $63.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $128.1 million in Q1 2021 to a low of $56.4 million in Q4 2025.
• A 5-year average of $93.2 million and a median of $95.0 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 67.4% — and 2025, when it tumbled 33.81%.
• Tracing RCEL's Liabilities and Shareholders Equity over 5 years: stood at $116.0 million in 2021, then retreated by 15.3% to $98.3 million in 2022, then rose by 13.61% to $111.6 million in 2023, then fell by 28.6% to $79.7 million in 2024, then fell by 29.25% to $56.4 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $56.4 million (Q4 2025), $63.7 million (Q3 2025), and $58.1 million (Q2 2025), per Business Quant data.